Pegaptanib治疗湿性年龄相关性黄斑变性的临床研究  

Clinical researches on Pegaptanib for the treatment of neovascular age-related macular degeneration

作　　者：李夏[1] 王雨生[1] 

机构地区：[1]第四军医大学西京医院眼科全军眼科研究所,中国陕西省西安市710032

出　　处：《国际眼科杂志》2006年第4期829-832,共4页International Eye Science

基　　金：中国国家自然科学基金资助项目(No.30371516);教育部留学回国人员科研启动基金资助项目(2004);第四军医大学科技创新工程资助项目(No.CX02A021)~~

摘　　要：年龄相关性黄斑变性(age-relatedmaculardegeneration,AMD)是发达国家老年人的主要致盲眼病,脉络膜新生血管(choroidalneovascularization,CNV)的形成是湿性AMD患者丧失视力的主要原因。CNV的发生机制尚不清楚,已证实血管内皮生长因子(vascularendothelialgrowthfac-tor,VEGF)是诱发CNV的关键因素之一。Pegaptanib作为眼科领域应用的第一种VEGF抑制剂,通过抑制CNV形成和血管渗漏,对湿性AMD已初步显示出较传统疗法更优越的治疗效果。随着对CNV发生机制的深入研究,针对病因进行治疗,将有可能更加有效的防治湿性AMD等CNV相关疾病。Age-related macular degeneration （AMD） is the leading cause of blindness among aged people in developed countries. The formation of choroidal neovascularization （CNV） is responsible for severe central vision loss associated with neovascular AMD. Although little is known on the mechanism of CNV, it is generally believed that vascular endothelial growth factor （VEGF） is implicated as the key factor in the provocation of CNV. Pegaptanib is the first anti-VEGF agent being used in the domain of ophthalmology which is designed to inhibit the formation of CNV and to block the permeability of vessel. It has exhibited a better curative effect than the conventional treatments. As researches on the mechanism of CNV go more deeper, treatments targeting the etiopathogenisis could be possible to help curing AMD and other CNV-related diseases.

关 键 词：年龄相关性黄斑变性 VEGF抑制剂 PEGAPTANIB MACUGEN EYE001 NX1838 

分 类 号：R774.5[医药卫生—眼科] R644[医药卫生—临床医学]